MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs ...

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) was the target of some unusual options trading on Thursday. Investors acquired 23,699 call options on the company. This is an increase ...

A comprehensive strategy that combines pharmacological advances, vector control, public outreach to raise awareness and ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...